Thermo Fisher Scientific to Acquire Affymetrix

Strengthens Leadership in Biosciences and Genetic Analysis
Significantly Expands Portfolio of Antibodies and Assays for High-Growth Flow Cytometry and Single-Cell Biology Applications
Adds Complementary Genetic Analysis Products Serving Research, Clinical and Applied Markets
Offers Opportunity to Leverage Thermo Fisher’s Commercial and Geographic Scale
Creates Attractive Financial Benefits; Expected to be Immediately Accretive to Adjusted Earnings per Share (EPS)

WALTHAM, Mass. and SANTA CLARA, Calif.--

Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and Affymetrix Inc. (AFFX), a leading provider of cellular and genetic analysis products, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion.

Giga-tronics Signs Software Agreement With Lockheed Martin

SAN RAMON, Calif., Dec. 01, 2015 -- Giga-tronics Incorporated (“the Company”) announced today that it has entered into a strategic software licensing arrangement with Lockheed Martin (“Lockheed Martin”) to develop and license threat simulation software as a commercial product that brings advanced threat environment simulation capability to its new Advanced Signal Generator Hardware Platform. The Company expects to be shipping the Advanced Signal Generator with the new software package within 6 months. The Software and Hardware will be sold together as a Real-Time Threat Emulation System (Real-Time TEmS), for distribution to US customers only.

Mark Elo, Vice President of Marketing of Giga-tronics, said “This is a win for the Electronic Warfare community, Lockheed Martin and Giga-tronics. The threat generation software is built by a team that has a strong legacy of program support and brings many new capabilities in a Commercial Off the Shelf solution that is both ready as a turnkey bench solution or a scalable alternative for larger projects.”

Opsens granted approval to sell OptoWire II in Japan

QUEBEC CITY, Nov. 26, 2015 - Opsens Inc. ("Opsens" or the "Company") (TSXV:OPS.V) (OTCQX:OPSSF) is pleased to announce that its Japanese partner has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW") to sell the OptoWire II.

OptoWire II for Improved Navigation in the Most Tortuous and Calcified Vessels

In its quest to offer the most effective products to measure Fractional Flow Reserve ("FFR") to cardiologists, Opsens has upgraded on its original OptoWire by adding a hydrophilic coating that improves navigation in the most tortuous and calcified vessels. This product, the OptoWire II, is following the regulatory path at an accelerated pace. Two weeks ago, Opsens announced receipt of CE marking, which grants permission to sell the OptoWire II in Europe. Clearance in the U.S. is expected shortly. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.

WaferGen Bio-systems Reports Strong Revenue Growth in Third Quarter of 2015

Highest Quarterly Revenue in Company History
WaferGen Updates Full-Year 2015 Revenue Guidance

FREMONT, Calif., Oct. 8, 2015-- WaferGen Bio-systems, Inc. (WGBS) today announced preliminary, unaudited revenue for the third quarter of 2015. The Company expects total revenue for the third quarter of 2015 to be in the range of $1.9 million to $2.1 million, which would represent an increase of 52-68% when compared to the $1.3 million reported for the third quarter of 2014. This also represents a sequential increase of 18-30% compared to the $1.6 million generated in the second quarter of 2015. Revenue for the third quarter is expected to be the highest in WaferGen's history, and represents the second consecutive quarter of revenue growth. The primary driver of revenue growth was sales of the Company's SmartChip^TM products and services, which comprised approximately 67% of total revenue, compared to 53% in the second quarter of 2015 and 58% in the third quarter of 2014.